**5. New therapies for HCV**

The advent of new drugs for the treatment of HCV infection, as well as polymerase and protease inhibitors, will considerably change the management of HCV infection due to their high antiviral power (Kwo et al, 2009, Hezode C et al, 2009). Around 50% of non-transplant patients who are difficult to treat because of the presence of factors predicting a lack of response have been shown to experience a greater sustained viral response (Aymant et, 2010). In transplanted patients, the increase in efficacy, applicability and tolerance, and the possible interactions with other drugs are as yet unknown and more studies are still required.
